Philip Morris International Opens Third Funding Round of PMI IMPACT
Philip Morris International Inc. (PMI) (NYSE: PM) is calling for applications for the third funding round of PMI IMPACT, the global initiative supporting projects that aim to reduce or prevent illegal trade and counter its negative consequences for individuals, their families, and communities. The third funding round will support a broad range of projects designed to tackle the multifaceted and multinational illicit trade—ranging from illicit tobacco products and other consumer goods to counterfeiting of pharmaceuticals and electronics—across different geographies. Now open for submissions, applicants from public, private, or nonprofit organizations, including governmental organizations, international organizations, associations, academic institutions, and private companies, are encouraged to submit their project proposals.
“Illicit trade knows no borders, and effective measures are needed to fight this international threat, which is a top priority for PMI as it undermines all our efforts toward delivering a smoke-free future—a future that can one day be without cigarettes,” said Alvise Giustiniani, Vice President, Illicit Trade Prevention. “The pandemic has also impacted supply chains, border controls and cross-border interactions, and now, more than ever, we need programs like PMI IMPACT that exchange expertise and bring together organizations, ideas, and solutions to eradicate illegal trade.”
Bringing innovation and technological advancement in the fight against contraband and counterfeited goods is essential, especially in the midst of the COVID-19 pandemic. This is why PMI IMPACT will be open to projects aimed at limiting the threats of counterfeited and substandard vaccines, medicines, medical supplies, and personal protective equipment.
Applicants can be based anywhere in the world; however, all proposals must address the funding round theme and focus on one of the following topics:
- Border control
- Capacity building
- Restorative justice and victims’ protection
- Network engagements, awareness building, and international cooperation
- COVID-19 and the threat of illicit trade
Interested third parties can apply for the third funding round before one of the three deadlines for submission of applications:
- First submission deadline: Sept. 15, 2021
- Second submission deadline: Feb. 15, 2022
- Third submission deadline: Aug. 15, 2022
PMI IMPACT is honored to be able to rely once again on the profound knowledge of the Expert Council, which is comprised of some of the world’s leading specialists in the field of law, human rights, anti-corruption, and technology. This council of external independent experts will play a central role in the evaluation and selection of the project proposals for the award of grants by PMI.
Navi Pillay, human rights advocate and member of the PMI IMPACT Expert Council, added:“PMI IMPACT offers a platform for organizations to bring resolutions to tackle the problematic reality of illegal trade. We are looking forward to evaluating the applications in the third funding round—the level of interest the initiative receives is truly remarkable. It is promising to see so many fantastic organizations working resolutely to fight illicit trade.”
Illegal trade remains a persistent and complex global problem. Its various forms—ranging from illicit tobacco trade to drugs, arms, and wildlife trafficking—are infinitely interlinked, with criminals exploiting large-scale smuggling routes and corrupt networks. Often operated by organized crime groups, illegal trade deprives governments and taxpayers of much needed revenues, takes business away from legitimate operators, deceives consumers with products of uncertain quality, and undermines society’s welfare and security.
Throughout the first and second funding rounds, PMI IMPACT has supported projects covering a range of activities making a lasting impact on illegal trade. We have worked with research programs to enhance knowledge on illegal trade, educational initiatives to improve public awareness of the issue, and we have helped fund the development of technological solutions to facilitate anti-illicit efforts. PMI had pledged USD 100 million to fund the first three rounds of grants; to date, PMI IMPACT has allocated a combined $48 million for the implementation of 60 projects in 30 countries as part of the initiative’s first and second funding rounds.
If you are interested in putting forward a proposal for PMI IMPACT’s third funding round, please contact the project office of PMI IMPACT at firstname.lastname@example.org. To find out more information on how to apply, please visit www.pmi-impact.com.
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company, its shareholders and its other stakeholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products, associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. In addition, PMI ships versions of its IQOS Platform 1 device and consumables to Altria Group, Inc. for sale under license in the U.S., where these products have received marketing authorizations from the U.S. Food and Drug Administration (FDA) under the premarket tobacco product application (PMTA) pathway; the FDA has also authorized the marketing of a version of IQOS and its consumables as a Modified Risk Tobacco Product (MRTP), finding that an exposure modification order for these products is appropriate to promote the public health. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI's smoke-free product portfolio includes heat-not-burn and nicotine-containing vapor products. As of March 31, 2021, PMI's smoke-free products are available for sale in 66 markets in key cities or nationwide, and PMI estimates that approximately 14.0 million adults around the world have already switched to IQOS and stopped smoking. For more information, please visit www.pmi.com and www.pmiscience.com.
# # #
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Philip Morris International
+54 911 3828 4288
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DXC Technology Completes Refinancing Actions24.9.2021 22:30:00 CEST | Press release
DXC Technology Company (NYSE: DXC) (“DXC”) today announced the completion of its refinancing. DXC previously completed the offering of €1.35 billion Senior Notes priced on September 2, 2021 and $1.35 billion Senior Notes priced on September 7, 2021. DXC completed redemption of $2.5 billion principal of (i) EUR term loan in the amount of €400 million due FY23 and FY24, (ii) $500 million 4.25% Senior notes due FY25, (iii) £250 million 2.75% Senior notes due FY25, (iv) $467 million 4.125% Senior notes due FY26, (v) $500 million 4.75% Senior notes due FY28, and (vi) $234 million Senior notes due FY30. The applicable make whole premium for these redemptions was $300 million and accrued and unpaid interest was $40 million. Ken Sharp, Chief Financial Officer, DXC commented: “Our opportunistic debt refinancing of $2.5 billion of our high coupon debt further solidifies our financial foundation by extending our debt maturities, lowering our maturity towers and reducing our ongoing interest expen
Schlumberger Announces Third-Quarter 2021 Results Conference Call24.9.2021 16:00:00 CEST | Press release
Schlumberger Limited (NYSE:SLB) will hold a conference call on October 22, 2021 to discuss the results for the third quarter ending September 30, 2021. The conference call is scheduled to begin at 9:30 am US Eastern time and a press release regarding the results will be issued at 7:00 am US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (844) 721-7241 within North America or +1 (409) 207-6955 outside of North America approximately 10 minutes prior to the start of the call and the access code is 8858313. A webcast of the conference call will be broadcast simultaneously at www.slb.com/irwebcast on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until November 22, 2021, and can be accessed by dialing +1 (866) 207-1041 within North America or +1 (402
Tradeweb Successfully Completes its First Southbound Bond Connect Transactions24.9.2021 14:07:00 CEST | Press release
Tradeweb Markets Inc. (Nasdaq: TW), a leading global operator of electronic marketplaces for rates, credit, equities and money markets, today announced it has completed its first Southbound Bond Connect transactions via the trading link between Tradeweb and China Foreign Exchange Trade System (CFETS). “Southbound Bond Connect is the latest evolutionary step for China’s financial market, providing domestic investors with more flexibility and choice when trading offshore bonds,” said Lee Olesky, CEO of Tradeweb Markets. “Together with CFETS, our goal is to better meet onshore investors’ demand for streamlined access to global investment. We will continue to focus on further enhancing the trading link by deploying new innovative trading functionality, just as we did with the Northbound leg of Bond Connect.” Southbound Bond Connect facilitates fixed income portfolio diversification for institutional investors in China. Tradeweb collaborates closely with CFETS to create a uniform trading ex
H.I.G. Capital Acquires Aspire Pharma24.9.2021 14:05:00 CEST | Press release
H.I.G. Capital, LLC (“H.I.G.”), a leading global alternative investment firm with $45 billion of equity capital under management, is pleased to announce that one of its affiliates has acquired Aspire Pharma Limited (“Aspire” or the “Company”), a leading UK provider of niche generic and branded specialty pharmaceuticals, alongside its founder Graham Fraser-Pye. The financial terms of the transaction have not been disclosed. Aspire licenses and develops niche generic and specialty pharmaceutical products that offer innovative formulations, value for money for payors, and reliable supply arrangements in markets that are often underserved. The business holds leadership positions in urology, ophthalmology, CNS and dermatology, with a highly diversified portfolio of more than 250 products across multiple categories, including branded specialty products and unbranded niche generics. H.I.G., together with the management team, aims to continue Aspire’s strong track record of organic growth and
Swappable Announces Partnership with Esports T1's Dota 2 Team24.9.2021 13:34:00 CEST | Press release
Swappable, an NFT (Non-Fungible Token) interface for high-profile and exclusive digital collectibles, has announced its partnership with T1's Dota 2 team, the popular esports team for the upcoming International 10 - Dota 2 World Championship in Bucharest, Romania. T1 is not just an esports team but a pop culture phenomenon with millions of fans worldwide. The team embodies a blend of lifestyle, creativity and attitude, fresh from the source of Seoul & LA. As part of the collaboration, T1 will auction their first-ever NFTs (digital collectibles) on Swappable for T1’s Genesis Collection. With the first auction starting Friday September 24th, T1 will release a series of NFTs each possessing utility features such as special access to T1's Dota 2 team players and more. Visit Swappable for more information. “We are excited to partner with a leading organization in the esports industry. It is also a chance for T1 fans to pick the very first digital collectibles ever created by this legendary
SAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-1924.9.2021 13:00:00 CEST | Press release
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that an independent Data Safety Monitoring Board (DSMB) has completed its prespecified interim analysis data review of the safety and efficacy of SAB-185 in the Phase 2 portion of the ACTIV-2 trial and has recommended advancement to Phase 3. SAB-185 is a fully-human, specifically-targeted, broadly-neutralizing polyclonal antibody therapeutic candidate for the treatment of non-hospitalized patients with mild to moderate COVID-19. It is being assessed in the ACTIV-2 trial funded and conducted by the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH) in collaboration with the AIDS Clinical Trials Group. SAB-185 is advancing to the Phase 3 trial based on meeting pre-defined graduation crite
NTHU Researchers Develop Ultrasonic Vortex Thrombolytic Device24.9.2021 11:00:00 CEST | Press release
As COVID-19 vaccination has raised the issue of thrombosis, Dr. Chih-Kuang Yeh, Distinguished Professor of the Department of Biomedical Engineering and Environmental Sciences, has led a research team to developed the world's first ultrasonic vortex thrombolytic device and to treat thrombosis quickly and safely. The research has been published in Proceedings of the National Academy of Sciences (PNAS) in 2021. Moreover, U.S. and EU patents are granted, with more applications on the way. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210924005015/en/ (Photo: National Tsing Hua University) The device is developed to solve two common thrombosis called pulmonary embolism (PE) and deep vein thrombosis (DVT), which have global prevalence of 10 million new cases annually. DVT is the main cause of PE, and PE can cause heart failure and has mortality rate up to 65%. Professor Yeh explained that the current treatment options includes dr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom